Canada Markets closed

Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine

TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE:PILL.CN) (CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it is the featured company in the Canadian CannaInvestor Magazine June 2019 Issue. The Canadian CannaInvestor Magazine is the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and the financial media. The digital version of the magazine is accessible and free to all subscribers who enter their email address. Canntab Therapeutics feature can be found by clicking on this link https://joom.ag/Q1xa.

About CanntabTherapeutics Limited

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

Frank Candido
Business Development
514-969-5530

frank@canntab.ca

Investor Relations

Relations Publiques Paradox Inc.
Jean-Francois Meilleur
1-866-460-0408
jfmeilleur@paradox-pr.ca
https://www.paradox-pr.ca/

Forward Looking Statements

Neither the Canadian Securities Exchange (the "CSE") nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE: Cannabis Investor Magazine



View source version on accesswire.com:
https://www.accesswire.com/549660/Canntab-Therapeutics-Featured-in-the-Canadian-Cannabis-Investor-Magazine